YU65995A - Inhibitori 5-lipoksigenaze i njihove farmaceutske kompozicije - Google Patents
Inhibitori 5-lipoksigenaze i njihove farmaceutske kompozicijeInfo
- Publication number
- YU65995A YU65995A YU65995A YU65995A YU65995A YU 65995 A YU65995 A YU 65995A YU 65995 A YU65995 A YU 65995A YU 65995 A YU65995 A YU 65995A YU 65995 A YU65995 A YU 65995A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- pharmaceutical compositions
- phenylene
- inhibitors
- lipoxygenasis
- treating
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- -1 oxy, thio, sulfinyl Chemical group 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000001989 1,3-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([H])C([*:2])=C1[H] 0.000 abstract 1
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000000168 pyrrolyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Opisani su inhibitori 5-lipoksigenaze formule: njihove farmaceutski primenljive soli i kompozicije, pri čemu Ar1 predstavlja 2-alkilimidazolil ili pirolil; X1 je direktna veza ili CH2; Ar2 je 1,4-fenilen; X2 je -A-X- ili -X-A-, gde je A direktna veza ili C1-4-alkilen, a X je oksi, tio, sulfinil ili sulfonil grupa, Ar3 je 1,3-fenilen ili 5-fluoro-1,3-fenilen; Y je CONH2; i R1 i R2 su svako C1-4 alkil. Ova jedinjenja su korisna pri tretiranju ili ublažavanju inflamatornih obolenja, alergija i kardiovaskularnih obolenja kod sisara i kao aktivni sastojak u farmaceutskim kompozicijama za tretiranje takvih stanja.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP9401747 | 1994-10-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| YU65995A true YU65995A (sh) | 1999-06-15 |
Family
ID=14098722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| YU65995A YU65995A (sh) | 1994-10-18 | 1995-10-17 | Inhibitori 5-lipoksigenaze i njihove farmaceutske kompozicije |
Country Status (31)
| Country | Link |
|---|---|
| EP (1) | EP0787127B1 (sh) |
| JP (1) | JP3032579B2 (sh) |
| CN (1) | CN1093536C (sh) |
| AT (1) | ATE198474T1 (sh) |
| AU (1) | AU681520B2 (sh) |
| BG (1) | BG61768B1 (sh) |
| CA (1) | CA2202057C (sh) |
| CO (1) | CO4480026A1 (sh) |
| CZ (1) | CZ287350B6 (sh) |
| DE (1) | DE69519804T2 (sh) |
| DK (1) | DK0787127T3 (sh) |
| ES (1) | ES2153033T3 (sh) |
| FI (1) | FI971632A0 (sh) |
| GR (1) | GR3035471T3 (sh) |
| HU (1) | HU221543B (sh) |
| IL (1) | IL115581A (sh) |
| LV (1) | LV11468B (sh) |
| MY (1) | MY114680A (sh) |
| NO (1) | NO314629B1 (sh) |
| NZ (1) | NZ285163A (sh) |
| PE (1) | PE49196A1 (sh) |
| PL (1) | PL180104B1 (sh) |
| RU (1) | RU2136666C1 (sh) |
| SI (1) | SI9500392A (sh) |
| SK (1) | SK281577B6 (sh) |
| TR (1) | TR199501274A2 (sh) |
| TW (1) | TW411339B (sh) |
| UA (1) | UA45312C2 (sh) |
| WO (1) | WO1996011911A1 (sh) |
| YU (1) | YU65995A (sh) |
| ZA (1) | ZA958748B (sh) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6239285B1 (en) | 1998-02-06 | 2001-05-29 | Pfizer Inc | Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems |
| US6194585B1 (en) * | 1998-12-22 | 2001-02-27 | Pfizer Inc. | Process for preparing 5-lipoxygenase inhibitors |
| SG87145A1 (en) * | 1999-08-31 | 2002-03-19 | Pfizer Prod Inc | Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems |
| US6344563B1 (en) * | 1999-08-31 | 2002-02-05 | Timothy Norris | Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems |
| US6346624B1 (en) * | 1999-08-31 | 2002-02-12 | Pfizer Inc | Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems |
| AU4589701A (en) | 2000-03-24 | 2001-10-08 | Cocensys Inc | Aryl substituted pyrazoles, triazoles and tetrazoles, and the use thereof |
| DK1383874T3 (da) * | 2001-04-20 | 2010-05-03 | Novozymes As | Varianter af lipogygenase og deres anvendelse |
| GB0302094D0 (en) | 2003-01-29 | 2003-02-26 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| GB0324269D0 (en) | 2003-10-16 | 2003-11-19 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| GEP20125386B (en) * | 2006-11-27 | 2012-01-25 | Pfizer Prod Inc | Pyrazole analogs |
| EP2225229A1 (en) | 2007-11-26 | 2010-09-08 | Pfizer Inc. | Pyrazole derivatives as 5-lo inhibitors |
| KR20140138243A (ko) * | 2012-02-28 | 2014-12-03 | 피라말 엔터프라이지즈 리미티드 | G 단백질 연결 수용체 작용물질로서의 페닐알칸산 유도체 |
| BR112020018094A2 (pt) | 2018-03-08 | 2020-12-22 | Incyte Corporation | Compostos de aminopirazina diol como inibidores de pi3k-¿ |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2001730A6 (es) * | 1987-01-14 | 1988-06-01 | Ferrer Int | Procedimiento de obtencion del acio 2,3-dihidro-5-(b-(1h-imidazol-1-il) etoxi)-1h-inden-1-carboxilico |
| EP0462830B1 (en) * | 1990-06-21 | 1995-10-18 | Zeneca Limited | Cyclic ether derivatives |
| IE913866A1 (en) * | 1990-11-28 | 1992-06-03 | Ici Plc | Aryl derivatives |
| EP0505122A1 (en) * | 1991-03-21 | 1992-09-23 | Zeneca Limited | Alpha, alpha-dialkylbenzyl derivatives |
| EP0540165A1 (en) * | 1991-10-03 | 1993-05-05 | Zeneca Limited | Alkanoic acid derivatives |
| ES2103130T3 (es) * | 1993-06-14 | 1997-08-16 | Pfizer | Inhibidores imidazoles como la lipoxigenasa. |
-
1994
- 1994-10-18 SK SK1287-95A patent/SK281577B6/sk unknown
-
1995
- 1995-05-29 NZ NZ285163A patent/NZ285163A/en unknown
- 1995-05-29 WO PCT/IB1995/000408 patent/WO1996011911A1/en not_active Ceased
- 1995-05-29 JP JP8513058A patent/JP3032579B2/ja not_active Expired - Fee Related
- 1995-05-29 ES ES95918121T patent/ES2153033T3/es not_active Expired - Lifetime
- 1995-05-29 EP EP95918121A patent/EP0787127B1/en not_active Expired - Lifetime
- 1995-05-29 AU AU24174/95A patent/AU681520B2/en not_active Ceased
- 1995-05-29 PL PL95319727A patent/PL180104B1/pl not_active IP Right Cessation
- 1995-05-29 DK DK95918121T patent/DK0787127T3/da active
- 1995-05-29 CZ CZ19971177A patent/CZ287350B6/cs not_active IP Right Cessation
- 1995-05-29 DE DE69519804T patent/DE69519804T2/de not_active Expired - Fee Related
- 1995-05-29 AT AT95918121T patent/ATE198474T1/de not_active IP Right Cessation
- 1995-05-29 HU HU9701853A patent/HU221543B/hu not_active IP Right Cessation
- 1995-05-29 CA CA002202057A patent/CA2202057C/en not_active Expired - Fee Related
- 1995-05-29 RU RU97106099/04A patent/RU2136666C1/ru not_active IP Right Cessation
- 1995-05-29 CN CN95195926A patent/CN1093536C/zh not_active Expired - Fee Related
- 1995-09-12 TW TW084109522A patent/TW411339B/zh not_active IP Right Cessation
- 1995-10-02 CO CO95045652A patent/CO4480026A1/es unknown
- 1995-10-12 IL IL11558195A patent/IL115581A/xx not_active IP Right Cessation
- 1995-10-13 UA UA95104510A patent/UA45312C2/uk unknown
- 1995-10-16 MY MYPI95003103A patent/MY114680A/en unknown
- 1995-10-17 PE PE1995282113A patent/PE49196A1/es not_active Application Discontinuation
- 1995-10-17 ZA ZA958748A patent/ZA958748B/xx unknown
- 1995-10-17 YU YU65995A patent/YU65995A/sh unknown
- 1995-10-17 LV LVP-95-313A patent/LV11468B/en unknown
- 1995-10-17 SI SI9500392A patent/SI9500392A/sl unknown
- 1995-10-18 BG BG100070A patent/BG61768B1/bg unknown
- 1995-10-18 TR TR95/01274A patent/TR199501274A2/xx unknown
-
1997
- 1997-04-17 FI FI971632A patent/FI971632A0/fi not_active IP Right Cessation
- 1997-04-17 NO NO19971773A patent/NO314629B1/no unknown
-
2001
- 2001-02-23 GR GR20010400310T patent/GR3035471T3/el not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| YU65995A (sh) | Inhibitori 5-lipoksigenaze i njihove farmaceutske kompozicije | |
| NO2006002I2 (no) | Posakonazol eventuelt i form av en ester og/eller et farmasøytisk akseptabelt salt derav. | |
| YU18101A (sh) | 4-amino supstituisani-2-supstituisani-1,2,3,4- tetrahidrohinolini kao inhibitori cetp | |
| YU69902A (sh) | Novi derivati piperazina | |
| EA200100202A1 (ru) | 4-карбоксиамино-2-замещенные-1,2,3,4-тетрагидрохинолины в качестве сетр-ингибиторов | |
| EA200100376A1 (ru) | Арилсульфонанилидмочевины | |
| MX9102209A (es) | Derivados de acido hidroxamico y n-hidroxiurea novedosos y su uso. | |
| ES2194986T3 (es) | Compuestos de carbonil-piperazinilo y piperidinilo que inhiben la farnesil-protein-transferasa. | |
| YU60198A (sh) | Supstituisani derivati indazola i njihova upotreba kao fosfodiesteraze (pde) tipa iv i inhibitora faktora nekroze tumora (tnf) | |
| EA200200262A1 (ru) | Пиперазиновые производные и их применение в качестве противовоспалительных агентов | |
| EA200101036A1 (ru) | Противовоспалительные и иммуносупрессорные соединения, ингибирующие клеточную адгезию | |
| PT1023267E (pt) | Compostos de piridilo e composicoes farmaceuticas que os contem | |
| NO158017C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive imidazolderivater. | |
| DE69315699D1 (de) | Inhibitoren gegen die aggregation von blutplättchen | |
| YU7191A (sh) | Oralno aktivni inhibitori renina | |
| YU6396A (sh) | Kombinacija inhibitora hiv proteaze sa drugim jedinjenjima za terapiju hiv infekcija | |
| ES2138211T3 (es) | N-hidroxiureas como agentes antiinflamatorios. | |
| DE69629474D1 (de) | Antifungale tetrahydrofurane | |
| DE69103773D1 (de) | Derivate von hydroxaminsäure die lipoxygenase hemmen. | |
| EA200200292A1 (ru) | Производные гигромицина | |
| EA199700302A1 (ru) | Биологически активные уреидо-производные, полезные при лечении рассеянного склероза | |
| YU32601A (sh) | Derivati higromicina kao antibakterijski agensi | |
| ATE146167T1 (de) | Cyclopropyl-n-hydroxyharnstoff als lypoxygenaseinhibitoren | |
| SE9902596D0 (sv) | Pharmaceutically active compounds | |
| ATE268768T1 (de) | Antithrombosemittel |